Author

Hartmut Goldschmidt

h-index 6 View on Semantic Scholar

We have 2 of 48 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.

In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myelom...

T. Facon, G. Cook, S. Usmani et al. · Leukemia · 0 citations

Open access Aug 2026

Latent effector T cells mediate immunotherapy responses in the bone marrow microenvironment.

TFiT (tumor-reactive features in T cells), a transcriptional classifier that identifies tumor-reactive T cells and stratifies immunotherapy, but not chemotherapy, response across independent MM and AML cohorts, supporting its specificity for T cell-mediated tumor control.

N. Kehl, T. Wagner, Simon Steiger et al. · Cancer Cell · 1 citation